Bellerophon Therapeutics Inc. said in a Form 8-K filing that Matthew Holt resigned as a director Dec. 11.
Further, the Bellerophon board elected CEO Fabian Tenenbaum as a director.
Discover more about S&P Global’s offerings
Bellerophon director resigns, CEO joins board
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Insight Weekly: Renewables lead capacity additions; bank mergers of equals up; nickel IPOs surge
Insight Weekly: Utilities face headwinds; S&P 500 dividend hikes likely; dollar poised for rally
Bellerophon Therapeutics Inc. said in a Form 8-K filing that Matthew Holt resigned as a director Dec. 11.
Further, the Bellerophon board elected CEO Fabian Tenenbaum as a director.